Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
VRCA compared with ANIK: revenue, margins and what each company keeps, and the suppliers and customers both name
VRCA
Verrica Pharmaceuticals Inc.
Change
Mkt cap
Revenue
Revenue
ANIK
Anika Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
VRCA
Verrica Pharmaceuticals Inc.
vs
ANIK
Anika Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
VRCA: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
VRCA, solid
ANIK, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only VRCA
1
—
Lytix BioPharma AS
unlisted
supplier
Shared
0
No shared counterparties.
Only ANIK
1
JNJ
Johnson & Johnson MedTech
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
VRCA
Verrica Pharmaceuticals Inc.
Change
3.20
▼
−4.48%
· post 3.27
· delayed
Mkt cap
$57.5M
Revenue
$6M
Q2 FY26
Revenue
$36M
FY25
ANIK
Anika Therapeutics, Inc.
Change
19.84
▼
−5.28%
· post 19.84
· delayed
After hours
Nov 2 '26
delayed
Mkt cap
$280.4M
Revenue
$33M
Q2 FY26
Revenue
$113M
FY25
vs
Compare
After hours
Nov 2 '26
delayed
VRCA
Verrica Pharmaceuticals Inc.
vs
ANIK
Anika Therapeutics, Inc.
3.20
▼
−4.48%
post 3.27
delayed
Price
19.84
▼
−5.28%
post 19.84
delayed
$57.5M
Mkt cap
$280.4M
Q2 FY26
$6M
Revenue
$33M
Q2 FY26
FY25
$36M
Revenue
$113M
FY25
Change
Change
VRCA
3.20
▼
−4.48%
vs
ANIK
19.84
▼
−5.28%
After hours
Nov 2 '26
delayed